GlassScriptPhysician profile
Kevin D Bigham
NPI 1225069792
$3,244.25
in general payments reported to CMS, 2019-2025
26 companies · $732 in 2025
The $732 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $240 · 2021: $534 · 2022: $509 · 2023: $374 · 2024: $639 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,745.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $614.33 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Johnson & Johnson Vision Care, INC. | $317.86 | 2019-2025 | |
| Oyster Point Pharma, INC. | $295.32 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $275.24 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $222.67 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Alcon Vision LLC | $213.20 | 2019-2025 | Dailies Total1, Eysuvis |
| Tarsus Pharmaceuticals, INC. | $182.74 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $160.51 | 2020-2023 | |
| Allergan, INC. | $146.87 | 2019-2022 | |
| Abbvie INC. | $108.40 | 2024-2025 | |
| Aerie Pharmaceuticals, INC. | $103.71 | 2020-2021 | |
| Rxsight INC | $88.24 | 2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Kala Pharmaceuticals, INC. | $80.50 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $73.67 | 2021 | |
| Dompe US, INC. | $67.60 | 2024-2025 | Oxervate |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $50.61 | 2022-2023 | |
| Carl Zeiss Meditec USA, INC. | $48.98 | 2021-2025 | Clarus |
| Maculogix, INC. | $34.59 | 2019-2020 | |
| Harrow Eye, LLC | $26.16 | 2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $23.34 | 2022 | |
| Amgen INC. | $21.92 | 2024 | Tepezza |
| Biotissue Holdings INC. | $21.65 | 2023 | |
| Horizon Therapeutics Plc | $21.35 | 2023 | Tepezza |
| Notal Vision, INC. | $18.93 | 2024 | Foresee Home |
| Johnson & Johnson Surgical Vision, INC. | $13.56 | 2019 | |
| Lumenis, INC | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Bigham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.